A detailed history of Koss Olinger Consulting, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Koss Olinger Consulting, LLC holds 10,000 shares of EDIT stock, worth $12,100. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Previous 10,000 -0.0%
Holding current value
$12,100
Previous $46,000 26.09%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$4.67 - $7.28 $46,700 - $72,800
10,000 New
10,000 $46,000
Q1 2023

May 12, 2023

BUY
$7.03 - $11.53 $70,300 - $115,300
10,000 New
10,000 $72,000
Q3 2021

Nov 09, 2021

SELL
$39.27 - $72.94 $1.26 Million - $2.34 Million
-32,100 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$39.71 - $90.58 $1.27 Million - $2.91 Million
32,100 New
32,100 $1.35 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $83.2M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Koss Olinger Consulting, LLC Portfolio

Follow Koss Olinger Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Koss Olinger Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Koss Olinger Consulting, LLC with notifications on news.